As Lindsey Vonn’s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the professional skier to its team, too.
The biotech, which is developing antibody-based treatments for infectious diseases, starting with COVID-19, has tapped Vonn for a partnership that will see her fronting an educational campaign about antibodies.
The campaign is slated to launch in the U.S. this spring, per Invivyd’s Thursday announcement, following the conclusion of the professional skiing season, which will see Vonn competing at her fifth Olympic Games after a 2024 knee replacement surgery reversed her 2019 retirement.
In the multimedia initiative, Vonn will provide information about antibodies and how they can help prevent disease, tying in the science to “broader conversations around health and wellness,” according to Invivyd.
“My athletic career has been about maximizing the potential of what my body can do: training hard, recovering smart, and learning to listen when it tells me something. My entire job is to take care of my body—I can’t afford to get sick,” Vonn said in the announcement. “That is why Invivyd’s mission to advance antibody science resonates with me, and I’m excited to collaborate with them on this important educational initiative.”
She added, “This movement is about helping everyone understand the potential to enhance their immune system, including antibody protection. Health shouldn’t be confusing or intimidating. It should be empowering.”
Invivyd emerged during the COVID-19 pandemic in 2020 as Adagio Therapeutics before rebranding to its current moniker in 2022.
After a roller-coaster few years attempting to get its first antibody-based COVID prevention-slash-treatment offering over the FDA finish line, Invivyd finally secured emergency use authorization for another monoclonal antibody for pre-exposure prophylaxis, now known as Pemgarda, in March 2024.
Alongside its slate of COVID-focused products, the company also has antibody-based therapies in early-stage development for RSV, measles and influenza, per its online pipeline listing.